Reading room

Peptides in Canada: product records.

Read Canadian peptide product records, regulatory notices and formulation distinctions. These guides separate medicine authorization, generic products, professional compounding, research labels and natural health product licences, using dated official sources.

Reset filters

Guides in this topic

1–10 of 10 guides

Page 1 of 1
Peptide rules in Canada. Drug: Specific authorization; Natural health product: Licence and conditions; Cosmetic: Different regulatory route.Research Practice

Are Peptides Legal in Canada? How Product Classification Works

Are peptides legal in Canada? There is no useful yes-or-no answer for the entire chemical category.

Updated 2026-11-06 ↗
BPC-157: three separate records. Study: A specified research model; COA: Reported sample tests; Authorization: A Canadian product record.Research Practice

BPC-157 in Canada: What Health Canada’s Notices Actually Say

BPC-157 in Canada is a product-status question as well as a research question. Health Canada’s public material identifies BPC-157 among ingredients encountered in unauthorized peptide products.

Updated 2026-11-06 ↗
Compounding and manufacturing. Patient-specific context: Regulated professional practice; Manufactured medicine: Federal product review; Read the actual record: Names alone do not decide.Research Practice

Compounded Semaglutide in Canada: How It Differs from an Authorized Generic

Compounded semaglutide in Canada should not be described as an authorized generic simply because it contains the same named ingredient. Compounding and commercial manufacturing have different regulatory contexts.

Updated 2026-11-06 ↗
Generic / compounded / research. Authorized generic: Own Canadian product record; Compounded preparation: Different practice framework; Research material: No inherited medicine record.Documentation & Traceability

Generic Semaglutide in Canada: Approval, Product Identity and Common Mix-Ups

Generic semaglutide in Canada is no longer just a future-market topic. Health Canada announced its first generic semaglutide authorization on 28 April 2026 and a second on 1 May 2026.

Updated 2026-11-06 ↗
Two tirzepatide product records. Mounjaro: Read its Canadian indications; Zepbound: Read its Canadian indications; Shared ingredient: GIP / GLP-1 receptor agonist.Peptide Fundamentals

Mounjaro vs Zepbound in Canada: Reading Tirzepatide Product Records

Mounjaro vs Zepbound compares two tirzepatide medicine brands. The shared ingredient does not erase the differences between their Canadian product records.

Updated 2026-11-06 ↗
Ozempic / Wegovy in Canada. Shared ingredient: Semaglutide; Different products: Check each monograph; Different evidence: Match population and endpoint.Peptide Fundamentals

Ozempic vs Wegovy in Canada: Same Ingredient, Different Product Records

Ozempic vs Wegovy is a comparison of finished medicines that share semaglutide. In Canada, the ingredient name is only the beginning of the record check.

Updated 2026-11-06 ↗
Match the DIN to the product. Label: Complete product details; Database: Name · company · route; Match: Status and current monograph.Documentation & Traceability

How to Check a Peptide Drug’s DIN in Canada

A peptide drug DIN check starts with an eight-digit Drug Identification Number and the exact product label. The number is a route into a Canadian product record.

Updated 2026-11-06 ↗
Research label / research pathway. RUO wording: A product label; Actual activity: Classify the real use; Human clinical trial: Dedicated authorization pathway.Research Practice

“Research Use Only” Peptides in Canada: What the Label Does Not Establish

Research use only peptides do not gain Canadian authorization simply from the words on a label. Health Canada’s current research guidance explicitly says that a research-use label does not make a product legal to import or sell.

Updated 2026-11-06 ↗
Retatrutide: research to product. Receptors: GLP-1 · GIP · glucagon; Clinical trials: Defined investigational product; Canadian status: Check the exact product.Research Practice

Retatrutide in Canada: Clinical Trials, Product Status and “GLP-3”

Retatrutide in Canada should be checked through both clinical-trial records and Canadian product information. These are separate records.

Updated 2026-11-06 ↗
Oral semaglutide is a formulation. Peptide ingredient: Semaglutide identity; Finished tablet: A defined formulation; Evidence and record: Match product and route.Peptide Fundamentals

Rybelsus in Canada: How Oral Semaglutide Differs from a Research Peptide

Rybelsus in Canada is an oral semaglutide medicine, not a generic label for any peptide taken by mouth. Its Health Canada product record identifies a prescription tablet with oral administration.

Updated 2026-11-06 ↗

Explore the related peptide dossiers

Peptides Canada: Product Status & Records | PeptideTwo